ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J. Souers, Steven W. Elmore, Peter Kovar et al.|Nature Medicine|2013Cited by 3k
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D. Leverson, Andrew J. Souers, Darren C. Phillips et al.|Science Translational Medicine|2015Cited by 541
Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208Andrew J. Souers, Steven W. Elmore, Erwin R. Boghaert et al.|Unknown|2013Cited by 182
The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>Jun Chen, Steven W. Elmore, Sha Jin et al.|Molecular Cancer Therapeutics|2011Cited by 149
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trialAndrew D. Zelenetz, Franck Morschhauser, Gilles Salles et al.|Blood|2019Cited by 136